NRG-GI008

Open to Accrual

Return to Protocol Table

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

Principal Investigator

Arvind Dasari, MD

Co-Principal Investigator(s)

Christopher Lieu, MD

Status

Open to Accrual

Open to Accrual

March 10, 2022


Disease Site

Gastrointestinal [GI] Colorectal

Phase

II/III

Developmental Therapeutics

No

Primary Objective

This Phase II/III trial will evaluate what kind of chemotherapy to
recommend to patients based on the presence or absences of circulating
tumor DNA (ctDNA) after surgery for colon cancer.

Patient Population

Men or women with Stage IIB, IIC, or Stage III colon cancer with R0 resection, and who are pMMR/MSS.

 

Target Accrual

1912

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.